University of São Paulo - Heart Institute and Hospital das Clínicas
Welcome,         Profile    Billing    Logout  
 11 Trials 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cukier, Alberto
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Hourglass Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD
Completed
3
806
Europe, Canada, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD DEVELOPMENT, LP
Pulmonary Disease, Chronic Obstructive
08/24
08/24
SPARTA, NCT01983241 / 2013-001870-38: Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)

Active, not recruiting
3
345
Europe, Canada, US, RoW
Alpha-1 MP, Prolastin-C, 0.9% Sodium Chloride for Injection, USP, Saline
Grifols Therapeutics LLC
Pulmonary Emphysema in Alpha-1 PI Deficiency
08/26
01/27
Pinto, Regina M Carvalho
No trials found
Stelmach, Rafael
No trials found

Download Options